Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Ranbaxy Posts Fourth-Quarter Loss on Legal Charge

By Pharmaceutical Processing | February 24, 2012

Ranbaxy reported Thursday a fourth-quarter loss of 29.8 billion rupees ($607 million), compared with a loss of 97.4 million rupees ($2 million) a year earlier, after taking a charge of $500 million to settle a legal dispute with U.S. authorities. Meanwhile, sales in the period rose 79 percent to 37.4 billion rupees ($761 million), helped in part by exclusive revenue in the U.S. from a generic version of Pfizer’s Lipitor.

“I am satisfied with the progress we are making in resolving the long standing issues with the U.S. regulators,” remarked CEO Arun Sawhney. The settlement and the provision set aside for the probe into compliance issues at manufacturing sites in the U.S. and India bring “greater predictability to our business in the US, one of our largest markets,” he added.

Sales in North America climbed by more than 230 percent to 19.7 billion rupees ($400 million) in the fourth quarter, boosted largely by the introduction of generic Lipitor with partner Teva. While the company declined to provide sales data on the statin, Bino Pathiparampil of IIFL Capital said sales were likely about $280 million, which is much higher than the $130 million he had estimated for the quarter. Under the terms of the partnership between the companies, Teva gets an undisclosed share of the profits from the first six months of sales of the product and IDFC Securities analyst Nitin Agarwal noted that while “the Lipitor numbers look pretty good…the payment to Teva is very high.” For the full year, sales in North America climbed 18 percent to 38.1 billion rupees ($775 million).

In addition, growth in the company’s Indian business slowed, with sales topping 4.8 billion rupees ($98 million) in the quarter and growing 7 percent for the full year to 19.5 billion rupees ($397 million). In Europe, quarterly sales held steady at 3.8 billion rupees ($77 million), while full-year sales grew 11 percent to 13.9 billion rupees ($283 million).

For the year ended December 31, the company posted a net loss of 29 billion rupees ($590 million) against a net profit of 15 billion rupees ($305 million) in 2010. Sales were up 13 percent at 99.8 billion rupees ($2 billion).

The drugmaker said it expects to achieve $2.2 billion in revenue this year, excluding any income from exclusive sales of generic drugs. “The guidance from the company is quite strong,” commented Kotak Institutional Equities analyst Priti Arora, adding that “I think the figure is pretty ambitious and may be difficult to achieve.”

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE